Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  PubMed  Google Scholar 

Chen Z, Chen J, Gao Y, Quan M. Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer. Expert Rev Anticancer Ther. 2021;21(10):1097–104. https://doi.org/10.1080/14737140.2021.1944108.

Article  CAS  PubMed  Google Scholar 

Benson AB, Venook AP, Al-Hawary MM, et al. Colon Cancer, Version 2.2021, NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–59. https://doi.org/10.6004/jnccn.2021.0012.

Article  PubMed  Google Scholar 

André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343–51. https://doi.org/10.1056/NEJMoa032709.

Guo Y, Xiong BH, Zhang T, Cheng Y, Ma L. XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis. Cancer Invest. 2016;34(2):94–104. https://doi.org/10.3109/07357907.2015.1104689.

Article  CAS  PubMed  Google Scholar 

Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306–15. https://doi.org/10.1016/S1470-2045(15)00122-9.

Article  CAS  PubMed  Google Scholar 

Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007;25(30):4779–86. https://doi.org/10.1200/JCO.2007.11.3357.

Article  CAS  PubMed  Google Scholar 

Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist. 2010;15(8):819–25. https://doi.org/10.1634/theoncologist.2009-0317.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317(23):2392–401. https://doi.org/10.1001/jama.2017.7105.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75. https://doi.org/10.1016/S1470-2045(14)70330-4.

Article  CAS  PubMed  Google Scholar 

Seufferlein T, Ettrich TJ, Stein A, et al. Predicting resistance to first-line FOLFOX plus bevacizumab in metastatic colorectal cancer: final results of the multicenter, international PERMAD trial. J Clin Oncol. 2021;39(3_suppl):115–115. https://doi.org/10.1200/JCO.2021.39.3_suppl.115.

Article  Google Scholar 

Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12. https://doi.org/10.1016/S0140-6736(12)61900-X.

Article  CAS  PubMed  Google Scholar 

Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619–29. https://doi.org/10.1016/S1470-2045(15)70156-7.

Article  CAS  PubMed  Google Scholar 

Van Cutsem E, Mayer RJ, Laurent S, et al. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2018;90:63–72. https://doi.org/10.1016/j.ejca.2017.10.009.

Article  CAS  PubMed  Google Scholar 

Pfeiffer P, Yilmaz M, Moller S, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(3):412–20. https://doi.org/10.1016/S1470-2045(19)30827-7.

Article  CAS  PubMed  Google Scholar 

Behjati S, Tarpey PS. What is next generation sequencing? Arch Dis Child Educ Pract Ed. 2013;98(6):236–8. https://doi.org/10.1136/archdischild-2013-304340.

Article  PubMed  PubMed Central  Google Scholar 

Bewicke-Copley F, Arjun Kumar E, Palladino G, Korfi K, Wang J. Applications and analysis of targeted genomic sequencing in cancer studies. Comput Struct Biotechnol J. 2019;17:1348–59. https://doi.org/10.1016/j.csbj.2019.10.004.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei Q, Zhang Y, Gao J, et al. Clinicopathologic characteristics of HER2-positive metastatic colorectal cancer and detection of HER2 in plasma circulating tumor DNA. Clin Colorectal Cancer. 2019;18(3):175–82. https://doi.org/10.1016/j.clcc.2019.05.001.

Article  CAS  PubMed  Google Scholar 

Chung C. Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: a 2021 update on current development, evidence, and recommendation. J Oncol Pharm Pract. 2021:10781552211005525. https://doi.org/10.1177/10781552211005525.

Fanelli GN, Dal Pozzo CA, Depetris I, et al. The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. Cancer Cell Int. 2020;20:30. https://doi.org/10.1186/s12935-020-1117-2.

Article  PubMed  PubMed Central  Google Scholar 

Golshani G, Zhang Y. Advances in immunotherapy for colorectal cancer: a review. Therap Adv Gastroenterol. 2020;13:1756284820917527. https://doi.org/10.1177/1756284820917527.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shiu K-K, Andre T, Kim TW, et al. KEYNOTE-177: phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer. J Clin Oncol. 2021;39(3_suppl):6–6. https://doi.org/10.1200/JCO.2021.39.3_suppl.6.

Article  Google Scholar 

Guarini C, Grassi T, Pezzicoli G, Porta C. Beyond RAS and BRAF: HER2, a new actionable oncotarget in advanced colorectal cancer. Int J Mol Sci. 2021;22(13):6813. https://doi.org/10.3390/ijms22136813.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bitar L, Zouein J, Haddad FG, Eid R, Kourie HR. HER2 in metastatic colorectal cancer: a new to target to remember. Biomark Med. 2021;15(2):133–6. https://doi.org/10.2217/bmm-2020-0491.

Article  CAS  PubMed  Google Scholar 

Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20(4):518–30. https://doi.org/10.1016/S1470-2045(18)30904-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Ross JS, Fakih M, Ali SM, et al. Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 2018;124(7):1358–73. https://doi.org/10.1002/cncr.31125. Lays out the differences between HER2 amplification and HER2 mutations and demonstrates the incidence of their association with other common alterations such as TP53, KRAS, and MSI.

Article  CAS  PubMed  Google Scholar 

Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2017;2(5):e000279. https://doi.org/10.1136/esmoopen-2017-000279.

Article  PubMed  PubMed Central  Google Scholar 

Yagisawa M, Sawada K, Nakamura Y, et al. Prognostic value and molecular landscape of HER2 low-expressing metastatic colorectal cancer. Clin Colorectal Cancer. 2021;20(2):113-120 e1. https://doi.org/10.1016/j.clcc.2020.11.002.

Article  PubMed  Google Scholar 

Siravegna G, Sartore-Bianchi A, Nagy RJ, et al. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin Cancer Res. 2019;25(10):3046–53. https://doi.org/10.1158/1078-0432.CCR-18-3389.